---
title: "MicroVision Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag"
description: "MicroVision (NASDAQ:MVIS) reported a net loss of $14.2 million for Q2 2025, a 41% improvement from Q2 2024, with an EPS of $0.056, beating expectations by 7.7%. However, revenue fell short of analyst "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252385319.md"
published_at: "2025-08-10T15:35:38.000Z"
---

# MicroVision Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

> MicroVision (NASDAQ:MVIS) reported a net loss of $14.2 million for Q2 2025, a 41% improvement from Q2 2024, with an EPS of $0.056, beating expectations by 7.7%. However, revenue fell short of analyst estimates by 74%. Looking ahead, revenue is projected to grow by 89% annually over the next three years, significantly outpacing the US Electronic industry’s 8.1% growth forecast. The company's share price remains stable, but there are four warning signs to consider.

## MicroVision (NASDAQ:MVIS) Second Quarter 2025 Results

### Key Financial Results

-   Net loss: US$14.2m (loss narrowed by 41% from 2Q 2024).
-   US$0.056 loss per share (improved from US$0.12 loss in 2Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

*All figures shown in the chart above are for the trailing 12 month (TTM) period*

### MicroVision EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 74%. Earnings per share (EPS) exceeded analyst estimates by 7.7%.

Looking ahead, revenue is forecast to grow 89% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Electronic industry in the US.

*Performance of the **American Electronic industry.***

The company's share price is broadly unchanged from a week ago.

### Risk Analysis

We don't want to rain on the parade too much, but we did also find **4 warning signs for MicroVision** (1 can't be ignored!) that you need to be mindful of.

### Related Stocks

- [MVIS.US - Microvision](https://longbridge.com/en/quote/MVIS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Peter Sutherland finds his footing in season 3 of 'Night Agent' | Peter Sutherland, played by Gabriel Basso, fully embraces his role as a covert operative in season 3 of 'The Night Agent | [Link](https://longbridge.com/en/news/276114142.md) |
| We tried a fiber-filled Diet Coke that could be sold in the US. It wasn't for everyone, but it won some fans. | We tried a fiber-filled Diet Coke that could be sold in the US. It wasn't for everyone, but it won some fans. | [Link](https://longbridge.com/en/news/276094531.md) |
| Public Investment Fund transfers share stake in Take-Two | Public Investment Fund transfers share stake in Take-Two | [Link](https://longbridge.com/en/news/276154110.md) |
| 'Not the Only Game in Town,' Says Top Investor About Netflix Stock | Top investor Dan Caplinger comments on Netflix's stock, which has dropped 18% this year, largely due to concerns over a  | [Link](https://longbridge.com/en/news/276138053.md) |
| Charli xcx closes 'brat summer' chapter with new mockumentary at Berlin Film Festival | Charli xcx premiered her mockumentary "The Moment" at the Berlin Film Festival, reflecting on her "brat summer" era that | [Link](https://longbridge.com/en/news/275987261.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.